Cordyceps for Respiratory and Lung Support

In Traditional Chinese Medicine, Cordyceps is above all a lung and kidney tonic, used for chronic cough, wheezing, and the breathlessness of aging — and this is one area where the traditional indication and modern laboratory findings genuinely rhyme. Animal models of asthma and chronic obstructive pulmonary disease (COPD) show that Cordyceps and cordycepin can dampen airway inflammation, reduce airway remodeling, and quiet the NF-κB and TGF-β signaling that drives chronic lung disease, and a small human trial reported improved quality of life and lung function in moderate-to-severe asthma. But the boundary is clear from the start: Cordyceps is a supplement, not a rescue inhaler or a controller medication. In the human asthma trial and the 2024 chronic obstructive pulmonary disease meta-analysis described below, it was given on top of standard treatment, not in place of prescribed asthma or chronic obstructive pulmonary disease therapy. This page lays out what the lung research shows and exactly where its limits are.


Table of Contents

  1. Cordyceps as a Lung Tonic
  2. The Traditional "Lung and Kidney" Rationale
  3. Asthma: Animal and Mechanistic Evidence
  4. Asthma: The Human Trial
  5. Chronic Obstructive Pulmonary Disease and Airway Remodeling
  6. Exercise, Breathing, and Oxygen Use
  7. Anti-Inflammatory Mechanisms in the Lung
  8. Practical Use and Firm Limits
  9. Cautions
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Cordyceps as a Lung Tonic

Of all the traditional Cordyceps indications, the respiratory ones are the oldest and most consistent. Classical Chinese texts prescribed it for chronic cough, phlegm, wheezing, and the "deficiency" breathlessness of the elderly and the convalescent. In modern China, mycelial Cordyceps capsule products are used clinically as adjuncts in chronic bronchitis and other lung conditions. That long, specific respiratory reputation is part of why lung disease has attracted more Cordyceps laboratory research than most of its other claimed uses.

Back to Table of Contents

The Traditional "Lung and Kidney" Rationale

In Traditional Chinese Medicine theory the lung and kidney are paired in the act of breathing: the lung "governs" respiration while the kidney "grasps" the breath. Chronic breathlessness was read as a failure of the kidney to anchor the lung's qi, and Cordyceps — classified as a warming kidney-and-lung tonic — was the signature remedy for exactly that pattern. One does not have to accept the metaphysics to notice that the clinical picture being described (chronic, progressive exertional breathlessness in older people) maps onto real modern diagnoses like chronic obstructive pulmonary disease and chronic bronchitis. The traditional framework, in other words, was pointing at a genuine clinical population, which is one reason the modern research has clustered around obstructive lung disease. The same lung-kidney framing is why Cordyceps also appears in kidney research, summarized in the Cochrane review cited below.

Back to Table of Contents

Asthma: Animal and Mechanistic Evidence

The strongest experimental case for Cordyceps in the lung comes from rodent asthma models, typically ovalbumin-sensitized mice that develop allergic airway inflammation. Across several independent studies:

Most of these findings point the same way: Cordyceps and cordycepin repeatedly down-regulate the same inflammatory pathways (NF-κB, key cytokines, TGF-β) that anti-inflammatory asthma drugs target, although in the mouse study that compared it directly with prednisolone and montelukast, Cordyceps militaris was the weaker agent. The caveat is equally consistent: these are animal and cell studies. Mouse airway inflammation is a model of human asthma, not human asthma itself, and many agents that quiet mouse airways never pan out in patients.

Back to Table of Contents

Asthma: The Human Trial

Human respiratory data for Cordyceps are scarce, which makes the trial by Wang and colleagues (2016) notable. 120 people with moderate-to-severe persistent asthma were randomized for 3 months: 60 took capsules containing Cordyceps sinensis on top of an inhaled corticosteroid and an as-needed beta-agonist inhaler, and 60 used the same inhalers with no capsule. Compared with the control group, the Cordyceps group showed a significant increase in health-related quality of life, measured with the Asthma Quality of Life Questionnaire (AQLQ), and in lung function, with lower blood levels of the inflammation markers IgE, ICAM-1, IL-4 and MMP-9 and higher IgG. The control group received no placebo capsule, and the abstract does not report any blinding.

What the trial does and does not show:

Cordyceps was tested here only as an add-on; no trial on this page tested it as a substitute for controller inhalers or rescue medication. The site's Asthma page describes the evidence-based mainstays.

Back to Table of Contents

Chronic Obstructive Pulmonary Disease and Airway Remodeling

Chronic obstructive pulmonary disease — the umbrella for chronic bronchitis and emphysema — is the modern diagnosis that best fits Cordyceps's traditional "deficiency breathlessness" niche. In a rat chronic obstructive pulmonary disease model, Cordyceps sinensis inhibited airway remodeling — the thickening and fibrosis of airway walls that makes obstruction permanent — again implicating reduced TGF-β-driven fibrotic signaling.

In Chinese clinical practice, mycelial Cordyceps capsule products have been studied as adjuncts in stable chronic obstructive pulmonary disease and chronic bronchitis, with some reports of improved symptoms and immune parameters. However, many of these trials are small, are conducted in Chinese-language settings, and are of variable methodological quality — the same limitation the Cochrane review of Cordyceps for chronic kidney disease flagged for the broader Cordyceps literature.

Two reviews pull these trials together. A 2019 systematic review of oral Cordyceps sinensis in stable chronic obstructive pulmonary disease of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 2–3 found 15 trials with 1,238 participants; it reported potential benefits in lung function, exercise endurance, quality of life and symptoms, with no serious adverse events reported, but "no studies were placebo-controlled or of high methodological quality, which limits the conclusions." A 2024 meta-analysis of 27 randomized trials of a capsule made from Cordyceps sinensis, given alongside standard therapy (the control groups received standard therapy alone or with other traditional Chinese medicines), reported significant improvements in forced expiratory volume in 1 second (FEV1), the FEV1/FVC (forced vital capacity) ratio and the 6-minute walk test, a marked reduction in acute flare-ups and better quality of life; its authors call for large-scale, multicenter randomized trials to confirm the long-term benefits and safety.

The result is a plausible, mechanistically supported case for a role in chronic obstructive pulmonary disease that has not yet been confirmed by large, rigorous, independent trials. The evidence-based management of chronic obstructive pulmonary disease is described on the site's chronic obstructive pulmonary disease page.

Back to Table of Contents

Exercise, Breathing, and Oxygen Use

Part of Cordyceps's respiratory reputation blends into its stamina reputation: the idea that it helps you breathe more efficiently under exertion. The exercise-performance evidence shows a modest improvement in the ventilatory threshold in older adults (Chen 2010), which is a breathing-related endpoint — the intensity at which ventilation climbs steeply. In that double-blind, placebo-controlled pilot trial, 20 healthy adults aged 50–75 took 333 mg capsules of a Cordyceps sinensis preparation or placebo 3 times a day for 12 weeks. On Cordyceps the ventilatory threshold rose by 8.5%, from 1.25 to 1.36 L/min, and the metabolic threshold (above which lactate builds up) by 10.5% (p < 0.02); the placebo group showed no significant change, and neither group changed in VO2 max (maximal oxygen uptake). This is consistent with the notion that Cordyceps may modestly ease the work of breathing during submaximal exertion in less-fit people, though as with the athletic claims, trained subjects show little effect. It is a real but small and population-dependent phenomenon, not a transformation of lung capacity.

Back to Table of Contents

Anti-Inflammatory Mechanisms in the Lung

The lung effects converge on a small set of mechanisms that recur throughout Cordyceps pharmacology:

Back to Table of Contents

Practical Use and Firm Limits

Back to Table of Contents

Cautions

Back to Table of Contents

Key Research Papers

  1. Wang N, Li J, Huang X, Chen W, Chen Y (2016). Herbal medicine Cordyceps sinensis improves health-related quality of life in moderate-to-severe asthma. Evid Based Complement Alternat Med — PubMed PMID: 28050193
  2. Hsu CH, Sun HL, Sheu JN, Ku MS, Hu CM, Chan Y, Lue KH (2008). Effects of the immunomodulatory agent Cordyceps militaris on airway inflammation in a mouse asthma model. Pediatr Neonatol 49(5):171-8 — PubMed PMID: 19133568
  3. Yang X, Li Y, He Y, Li T, Wang W, Zhang J, Wei J, Deng Y, Lin R (2015). Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. Int Immunopharmacol 26(2):401-8 — PubMed PMID: 25912153
  4. Zheng Y, Li L, Cai T (2020). Cordyceps polysaccharide ameliorates airway inflammation in an ovalbumin-induced mouse model of asthma via TGF-β1/Smad signaling pathway. Respir Physiol Neurobiol 276:103412 — PubMed PMID: 32044448
  5. Chiou YL, Lin CY (2012). The extract of Cordyceps sinensis inhibited airway inflammation by blocking NF-κB activity. Inflammation 35(3):985-93 — PubMed PMID: 22068667
  6. Yang L, Jiao X, Wu J, et al. (2018). Cordyceps sinensis inhibits airway remodeling in rats with chronic obstructive pulmonary disease. Exp Ther Med 15(3):2731-2738 — PubMed PMID: 29456676
  7. Yu X, Mao Y, Shergis JL, Coyle ME, Wu L, Chen Y, Zhang AL, Lin L, Xue CC, Xu Y (2019). Effectiveness and safety of oral Cordyceps sinensis on stable COPD of GOLD stages 2-3: systematic review and meta-analysis. Evid Based Complement Alternat Med 2019:4903671 — PubMed PMID: 31073318
  8. Ma G, Jin Y (2024). Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology. Pharm Biol 62(1):803-817 — PubMed PMID: 39460586
  9. Chen S, Li Z, Krochmal R, Abrazado M, Kim W, Cooper CB (2010). Effect of Cs-4 (Cordyceps sinensis) on exercise performance in healthy older subjects: a double-blind, placebo-controlled trial. J Altern Complement Med 16(5):585-90 — PubMed PMID: 20804368
  10. Zhang HW, et al. (2014). Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease. Cochrane Database Syst Rev — PubMed PMID: 25519252
  11. Zhu JS, Halpern GM, Jones K (1998). The scientific rediscovery of an ancient Chinese herbal medicine: Cordyceps sinensis, Part I. J Altern Complement Med — PubMed PMID: 9764768

PubMed Topic Searches

  1. PubMed: Cordyceps asthma / airway inflammation
  2. PubMed: Cordyceps & COPD
  3. PubMed: Cordyceps chronic bronchitis
  4. PubMed: Cordycepin, lung & NF-κB

Back to Table of Contents

Connections

Back to Table of Contents